EVMN
Evommune, Inc. NYSE Listed Nov 6, 2025$25.18
+4.35%
vs $24.13
Mkt Cap $793.8M
52w Low $15.01
61.4% of range
52w High $31.57
50d MA $23.09
200d MA $22.04
P/E (TTM)
—
EV/EBITDA
—
P/B
3.9x
Debt/Equity
0.0x
ROE
-33.5%
P/FCF
-10.4x
RSI (14)
76.50
ATR (14)
$1.57
Beta
2.31
50d MA
$23.09
200d MA
$22.04
Avg Volume
513.0K
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
1841 Page Mill Road · Palo Alto, CA 94304 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | -0.82 | -1.43 | -74.4% | 25.09 | -1.0% | +5.6% | -7.1% | -2.5% | -2.5% | -1.8% | — |
| Dec 11, 2025 | AMC | -6.08 | -8.07 | -32.7% | 19.69 | -2.1% | -8.5% | -2.1% | -10.0% | +0.4% | -5.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Stifel | Initiates | Buy | $54 | $23.80 | $24.43 | +2.6% | +2.9% | -3.6% | +2.2% | -1.4% | -5.6% |
| Apr 10 | RBC Capital | Maintains | Outperform → Outperform | — | $28.65 | $28.50 | -0.5% | -11.0% | +5.9% | -1.4% | +1.2% | -0.6% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.03 | $25.30 | +1.1% | -3.8% | -2.2% | -1.0% | +0.5% | -10.4% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.99 | $29.52 | +73.7% | +70.9% | -2.0% | -2.0% | +13.2% | -1.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 22, 2026 | Pena Luis C. | President & CEO | Sell | 7,438 | $22.71 | $169K | 630,458 | +2.42% | — |
| Jun 22, 2026 | Drew Janice Suzann | Chief of Dev. Operations | Sell | 20,000 | $22.63 | $453K | 67,794 | +2.42% | — |
| Jun 22, 2026 | Patel Jeegar Pravinkumar | Chief Scientific Officer | Sell | 1,488 | $22.50 | $33K | 46,403 | +2.42% | — |
| Jun 2, 2026 | Cohen David E | — | Sell | 600 | $21.38 | $13K | 17,609 | +4.87% | +0.00% |
| Jun 2, 2026 | Cohen David E | — | Sell | 5,456 | $20.21 | $110K | 18,209 | +4.87% | +0.00% |
| Jun 1, 2026 | Pena Luis C. | President & CEO | Sell | 16,787 | $22.74 | $382K | 637,896 | +4.87% | +0.00% |
| Jun 1, 2026 | Patel Jeegar Pravinkumar | Chief Scientific Officer | Sell | 16,687 | $22.74 | $379K | 46,403 | +4.87% | +0.00% |
| May 28, 2026 | Moss Gregory S. | Chief Business & Legal Officer | Sell | 14,223 | $22.83 | $325K | 60,835 | -10.60% | +1.36% |
| May 28, 2026 | Carver Kyle | Chief Financial Officer | Sell | 18,175 | $22.84 | $415K | 59,335 | -10.60% | +1.36% |
8-K · 2.02
!! High
Evommune, Inc. -- 8-K 2.02: Earnings Results
Evommune disclosed operating results and financial condition updates via press release, providing investors transparency on company performance metrics and current financial standing.
May 7
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Evommune disclosed migraine research on MRGPRX2, suggesting potential pipeline advancement; investors should monitor clinical progress as this targeting could represent a significant market opportunity if successful.
Apr 13
8-K · 7.01
! Medium
Evommune, Inc. -- 8-K 7.01: Regulation FD Disclosure
Evommune updated its investor presentation with business updates, providing shareholders current information about company operations and strategy.
Mar 5
8-K · 1.01
! Medium
Evommune, Inc. -- 8-K 1.01: Equity Issuance
Evommune issued $125 million in securities to raise capital, diluting existing shareholders but strengthening the company's financial position for operations and development.
Feb 13
8-K · 8.01
!! High
Evommune, Inc. -- 8-K 8.01: Material Event / Announcement
I cannot provide a specific analysis as the summary lacks details about the material event announcement; the actual content from Exhibit 99.1 is needed to determine investment implications for Evommune.
Feb 10
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Andera Partners | 1,897,362 | $44M | — | Mar 2026 |
| 2 | Rtw Investments, Lp | 1,502,235 | $35M | Added | Mar 2026 |
| 3 | Mpm Bioimpact Llc | 1,455,863 | $33M | Added | Mar 2026 |
| 4 | Nan Fung Group Holdings Ltd | 1,441,032 | $33M | — | Mar 2026 |
| 5 | Jpmorgan Chase & Co | 1,459,420 | $32M | Added | Mar 2026 |
| 6 | Janus Henderson Group Plc | 896,700 | $21M | New | Mar 2026 |
| 7 | Marshall Wace, Llp | 879,728 | $20M | Reduced | Mar 2026 |
| 8 | Alyeska Investment Group, L.p. | 726,362 | $17M | New | Mar 2026 |
| 9 | Defilade Capital Management, L.p. | 678,589 | $16M | Added | Mar 2026 |
| 10 | Vanguard Capital Management Llc | 455,051 | $10M | New | Mar 2026 |
| 11 | Velan Capital Investment Management Lp | 446,255 | $10M | Reduced | Mar 2026 |
| 12 | Ubs Group Ag | 298,375 | $7M | Added | Mar 2026 |
| 13 | E Fund Management Co., Ltd. | 243,700 | $6M | New | Mar 2026 |
| 14 | Stempoint Capital Lp | 193,777 | $4M | New | Mar 2026 |
| 15 | Adar1 Capital Management, Llc | 184,062 | $4M | New | Mar 2026 |
| 16 | Blue Owl Capital Holdings Lp | 100,000 | $2M | New | Mar 2026 |
| 17 | Northern Trust Corp | 79,755 | $2M | Added | Mar 2026 |
| 18 | Vanguard Portfolio Management Llc | 60,993 | $1M | New | Mar 2026 |
| 19 | Seven Grand Managers, Llc | 75,000 | $1M | New | Dec 2025 |
| 20 | Propel Bio Management, Llc | 55,664 | $1M | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$793.8M
Enterprise Value
$644.6M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
1.98x
P/B
3.86x
P/S
79.38x
P/FCF
-10.35x
EV/EBITDA
—
Shares Out
31.5M
Financials (TTM)
Revenue
$10.0M
Net Income
-$76.0M
EBITDA
-$74.6M
Free Cash Flow
-$76.7M
Op Cash Flow
-$76.4M
EPS Basic
$-2.18
EPS Diluted
$-2.39
EPS Forward
$-3.13
Gross Margin
92.8%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$224.9M
Total Liab.
$19.4M
Total Equity
$205.6M
Cash
$149.2M
LT Debt
$0
Book Value/Sh
$6.52
Debt/Equity
0.01x
Current Ratio
8.57
Quick Ratio
8.57
Returns & Growth
ROE
-33.5%
ROA
-30.6%
ROIC
-39.1%
Rev Growth YoY
+85.7%
EPS Growth YoY
+4.0%
Price Returns
2W
+2.2%
1M
-2.4%
3M
-10.7%
6M
+12.2%
12M
+14.8%
Technicals
52W High
$31.57
52W Low
$15.01
50d MA
$23.09
200d MA
$22.04
RSI (14)
76.50
ATR (14)
$1.57
Beta
2.31
Avg Volume
513K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$49.67
High
$65.00
Low
$40.00
Median
$48.00
Data updated apr 25, 2026 8:01am
· Source: financialmodelingprep.com